RCUS · Arcus Biosciences, Inc.
$29.48
+0.62 (+2.15%)
At close · Aug 14
Market Cap
$3.75B
Shares
127.33M
Arcus Biosciences, Inc. Earnings Call Transcripts
Every quarterly earnings call for Arcus Biosciences, Inc. (RCUS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲185.4%
$27.00M
−$67.00M
'22 Q2
22-08-03
▲248.8%
$33.00M
−$65.00M
'22 Q3
22-11-02
▼90.4%
$34.00M
−$67.00M
'22 Q4
23-02-28
▲38.9%
$25.00M
−$80.00M
'23 Q1
23-05-09
▲7.4%
$29.00M
−$75.00M
'23 Q2
23-08-07
▼3%
$32.00M
−$71.00M
'23 Q3
23-11-07
▼8.8%
$31.00M
−$81.00M
'23 Q4
24-02-21
▲480%
$145.00M
−$4.00M
'24 Q1
24-05-08
▲34.5%
$39.00M
−$93.00M
'24 Q2
24-08-08
▲50%
$48.00M
−$92.00M
'24 Q3
24-11-06
▼16.1%
$26.00M
−$94.00M
'24 Q4
25-02-25
▼80.7%
$28.00M
−$112.00M
'25 Q1
25-05-06
▲310.3%
$160.00M
$
'25 Q2
25-08-06
▲26.9%
$33.00M
−$106.00M
'25 Q4
26-02-25
▼39.3%
$17.00M
−$128.00M
'26 Q1
26-05-05
LATEST
▼74.4%
$41.00M
−$91.00M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Arcus Biosciences Second Quarter 2026 Earnings
Confident tone
Belzutafan durability and HIF2 mechanism thesis
ARC-20 platform study and data readouts
Competitive positioning after LightSpark 012 failure
Revenue
$41.00M
▼ 74.4% YoY Diluted EPS
$-0.72
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Fireside Chat - Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Arcus Biosciences, Inc. Q1 FY2026 Earnings Call
Confident tone
Cascadifan lead program and differentiation
Frontline RCC strategy and combinations
PEEK-1 Phase 3 enrollment and timeline
Revenue
$17.00M
▼ 39.3% YoY Diluted EPS
$-1.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-09
Fireside Chat - Leerink Global Healthcare Conference 2026
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-25
Arcus Biosciences, Inc. Q4 FY2025 Earnings Call
Confident tone
Frontline TKI-sparing strategy
Casdatifan HIF2a inhibitor differentiation
Peak One Phase 3 in IO-experienced RCC
Revenue
$33.00M*
▲ 26.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q2
2025-08-06
Arcus Biosciences, Inc. Q2 FY2025 Earnings Call
Revenue
$160.00M
▲ 310.3% YoY Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Arcus Biosciences, Inc. Q1 FY2025 Earnings Call
Confident tone
Casdatifan (cas) program prioritization
ASCO oral presentation and data flow
Casdatifan combinations and earlier-line opportunity
Revenue
$28.00M
▼ 80.7% YoY Diluted EPS
$-1.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Arcus Biosciences, Inc. Q4 FY2024 Earnings Call
Revenue
$26.00M*
▼ 16.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Arcus Biosciences, Inc. Q3 FY2024 Earnings Call
Confident tone
Dom Zim Phase 3 trials (STAR-121, STAR-221, Pacific-8)
ARC-20 study data updates and future readouts
Domvanalimab (Fc-silent anti-TIGIT) and ARC-10 data
Revenue
$48.00M
▲ 50% YoY Diluted EPS
$-1.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Arcus Biosciences, Inc. Q2 FY2024 Earnings Call
Revenue
$39.00M
▲ 34.5% YoY Diluted EPS
$-1.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Arcus Biosciences, Inc. Q1 FY2024 Earnings Call
Confident tone
Casdatifan (cas) in clear cell RCC vs. Novartis HIF-2
Quemliclustat (quemli) in pancreatic cancer
ASCO 2024 oral presentations and upcoming catalysts
Revenue
$145.00M
▲ 480% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-21
Arcus Biosciences, Inc. Q4 FY2023 Earnings Call
Confident tone
Casdatifan (AB521) HIF-2alpha inhibitor
Anti-TIGIT (domvanalimab/zimberelimab, dom/zim) program
Quemliclustat (quemli) CD73 inhibitor in pancreatic cancer
Revenue
$31.00M*
▼ 8.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Arcus Biosciences, Inc. Q3 FY2023 Earnings Call
Revenue
$32.00M
▼ 3% YoY Diluted EPS
$-0.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Arcus Biosciences, Inc. Q2 FY2023 Earnings Call
Revenue
$29.00M
▲ 7.4% YoY Diluted EPS
$-1.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Arcus Biosciences, Inc. Q1 FY2023 Earnings Call
Revenue
$25.00M
▲ 38.9% YoY Diluted EPS
$-1.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Arcus Biosciences, Inc. Q4 FY2022 Earnings Call
Revenue
$34.00M*
▼ 90.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Arcus Biosciences, Inc. Q3 FY2022 Earnings Call
Revenue
$33.00M
▲ 248.8% YoY Diluted EPS
$-0.90
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Arcus Biosciences, Inc. Q2 FY2022 Earnings Call
Revenue
$27.00M
▲ 185.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Arcus Biosciences, Inc. Q1 FY2022 Earnings Call
Revenue
$18.00M
▲ 90.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Arcus Biosciences, Inc. Q4 FY2021 Earnings Call
Revenue
$354.62M*
▲ 3637.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-18
Arcus Biosciences, Inc. Q3 FY2021 Earnings Call
Revenue
$9.46M
▼ 85.3% YoY Diluted EPS
$-1.11
▼ 3800% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Arcus Biosciences, Inc. Q2 FY2021 Earnings Call
Revenue
$9.46M
▲ 440.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–22 of 22 earnings calls
Key facts
CIK
1724521
CUSIP
03969F109
13F (30d)
217 filings
216 filers
Visit website
Investor relations